ASCLF
Ascletis Pharma Inc.
Set alert
0.72 USD 0.00 0.00%
0.72 Day range 0.72
0.72 52-week range 2.50
- YTD
- -51.68%
- 1 year
- -40.00%
- Open
- 0.72
- Prev close
- 0.72
- Mkt cap
- 756.97M
- Vol
- 5.00K
- Avg vol
- 934
- EPS
- -0.08
- P/E
- 0.00
More statistics
- Low
- 0.72
- High
- 0.72
- Earnings
- Aug 31, 2026
Next earnings
Aug 31, 2026
Expected Aug 31, 2026. Consensus EPS estimate -0.02944.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 31, 2026 | Jun 30, 2026 | -0.02944 | — | — | — |
| Mar 31, 2026 | Dec 31, 2025 | -0.04003 | -0.04003 | 0.00 | 0.00% |
| Aug 15, 2025 | Jun 30, 2025 | -0.01814 | -0.01275 | +0.01 | +29.71% |
| Mar 26, 2025 | Mar 31, 2025 | -0.02054 | -0.02328 | 0.00 | -13.34% |
| Aug 30, 2024 | Jun 30, 2024 | -0.01651 | -0.01764 | 0.00 | -6.84% |
| May 22, 2024 | Mar 31, 2024 | 0.00147 | — | — | — |
News
- Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
- Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
- Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
- Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
- Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
- Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
- Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
- Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
- Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
- Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
Your note
Sign in to keep a note on ASCLF — it syncs with the Stock Master app.